Loading

Commentary Open Access
Volume 2 | Issue 1 | DOI: https://doi.org/10.46439/immunol.2.012

BRCA1 and BRCA2 mutation variants in early breast cancer confer added prognostic information

  • 1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • 2Department of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
+ Affiliations - Affiliations

Corresponding Author

Nuhad K. Ibrahim, nibrahim@mdanderson.org

Received Date: September 28, 2022

Accepted Date: January 03, 2023

Abstract

Metastatic breast cancer to brain carries poor prognostic features with increased risks of occurrence in Tripple- negative and HER- positive breast tumors. In addition, tumors with mutated BRCA tumors, carry as well increased metastatic incidence. However, new clinical evidence suggest distinct clinical features between BRCA1 or BRCA2 mutated breast cancer and brain metastasis. Review of literature may help characterize the distinctive differences between BRCA1 or BRCA2 breast tumors and subsequent metastasis to brain.

Keywords

Breast cancer, Brain metastasis, BRCA1, BRCA2, Mutation, Triple-negative, Hormone -receptor positive, Pathogenic variant, Prognosis, Early breast cancer

Author Information X